Last reviewed · How we verify
PF-06651600 Maintenance Dose #3
At a glance
| Generic name | PF-06651600 Maintenance Dose #3 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (PHASE3)
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects (PHASE2)
- PF-06651600 for the Treatment of Alopecia Areata (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |